Erlotinib in Treating Women Undergoing Surgery For Stage I, Stage II, or Stage III Breast Cancer
NCT ID: NCT00503841
Last Updated: 2019-04-30
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
44 participants
INTERVENTIONAL
2007-12-31
2010-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This clinical trial is studying how well erlotinib works in treating women undergoing surgery for stage I, stage II, or stage III breast cancer.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Ph II Letrozole + OSI-774 (Tarceva) in Post-menopausal, w/ ER and/or PR-positive Met Breast Cancer.
NCT00611715
Everolimus in Treating Women With Breast Cancer That Can Be Removed by Surgery
NCT00855114
Phase 2, Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-sensitive Metastatic Breast Cancer
NCT01013506
Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer
NCT03128619
Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-Sensitive Metastatic Breast Cancer
NCT01205685
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Primary
* To estimate the effect of erlotinib hydrochloride on expression of interleukin (IL)-1α in patients with estrogen receptor (ER-)-negative, EGFR-positive and IL-1α-positive breast cancer.
Secondary
* To estimate the effect of erlotinib hydrochloride on expression of nuclear NF-κB and amphiregulin (AR) in patients with ER-negative, EGFR-positive and IL-1α-positive breast cancer.
* To estimate the effect of erlotinib on tumor cell proliferation (Ki67) and apoptosis (TUNEL).
* To estimate the rates of IL-1α, nuclear NF-κB, and AR expression in patients with ER-negative, EGFR-positive breast cancer.
* To follow the clinical course of patients with resectable ER-negative, EGFR-positive and IL-1α-positive breast cancer.
* To assess the toxicity of a 15-day regimen of daily oral administration of erlotinib hydrochloride in participants with ER-negative, EGFR-positive and IL-1α-positive breast cancer.
OUTLINE: This is an open-label, pilot study. Patients are stratified according to HER2 status (positive vs negative).
Patients receive oral erlotinib hydrochloride once daily on days -14 to 0 in the absence of disease progression or unacceptable toxicity.
Patients undergo surgery on day 0.
Tissue samples are collected at baseline and examined for expression of estrogen receptor, progesterone receptor, HER2, EGFR, interleukin (IL)-1α, amphiregulin, and NF-kB. Tissue samples collected at surgery are examined for IL-1α, NF-kB, and amphiregulin by IHC.
Following surgery, patients will be contacted 1 week post-surgery (± 1 day) or 1 week post-withdrawal from study (± 1 day) by phone call or clinic visit to assess toxicity. After that, patients will be followed and treated according to standard of care practices. If patients choose to follow-up with an oncologist outside of our institution, they or their oncologist will be contacted every 6 months for updated information on their conditions.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
erlotinib hydrochloride
Patients receive erlotinib hydrochloride PO (orally) QD (every day) on days -14-0 immediately prior to scheduled surgery. Treatment continues in the absence of disease progression or unacceptable toxicity.
erlotinib hydrochloride
Patients receive erlotinib hydrochloride PO (orally) QD (every day) on days -14-0 immediately prior to scheduled surgery. Treatment continues in the absence of disease progression or unacceptable toxicity.
immunohistochemistry staining method
Assessed at the time of the initial biopsy and at the time of surgery.
laboratory biomarker analysis
Correlative studies
biopsy
14 days prior to surgery
conventional surgery
14 days after taking study drug erlotinib hydrochloride.
neoadjuvant therapy
14 days after taking study drug erlotinib hydrochloride.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
erlotinib hydrochloride
Patients receive erlotinib hydrochloride PO (orally) QD (every day) on days -14-0 immediately prior to scheduled surgery. Treatment continues in the absence of disease progression or unacceptable toxicity.
immunohistochemistry staining method
Assessed at the time of the initial biopsy and at the time of surgery.
laboratory biomarker analysis
Correlative studies
biopsy
14 days prior to surgery
conventional surgery
14 days after taking study drug erlotinib hydrochloride.
neoadjuvant therapy
14 days after taking study drug erlotinib hydrochloride.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Stage I-III disease
* BI-RADS 4 or 5 abnormalities on breast imaging and undergoing core needle biopsy for diagnosis
* Participants must have a lesion of at least 1-cm on breast imaging studies (mammogram, ultrasound, or MRI)
* Participants must have breast cancer amenable to surgery with curative intent and must have agreed to undergo such surgery
* The surgical procedure must be scheduled in the near future to accommodate a treatment period of no less and no more than 15 days
* Clinically positive for the overexpression of EGFR and interleukin-1α
* Clinically negative for expression of the estrogen receptor (ER-negative) and progesterone receptor (PgR-negative)
* May be positive or negative for HER2
Exclusion
* Locally advanced or metastatic disease not amenable to surgery
* Known brain metastases
PATIENT CHARACTERISTICS:
Inclusion
* Female
* Menopausal status not specified
* ECOG performance status (PS) 0-2 or Karnofsky PS 60-100%
* ANC ≥ 1000/mm³
* Platelet count ≥ 75,000/mm³
* AST and ALT ≤ 2.5 times upper limits of normal (ULN)
* Alkaline phosphatase ≤ 2.5 times ULN
* Bilirubin ≤ 2 times ULN
* Hemoglobin \> 9 g/dL
* Creatinine within normal institutional limits OR creatinine clearance \>60 mL/min
* Negative serum pregnancy test within 7 days of enrollment for pre-menopausal women and women within 6 months of menopause
* Women of child-bearing potential and their partners must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation
Exclusion
* Pregnant or nursing
* History of allergic reactions attributed to compounds of similar chemical or biologic composition to erlotinib hydrochloride
* Uncontrolled intercurrent illness including, but not limited to, any of the following:
* Ongoing or active infection
* Symptomatic congestive heart failure
* Unstable angina pectoris
* Cardiac arrhythmia
* Psychiatric illness/social situations that would limit compliance with study requirements
PRIOR CONCURRENT THERAPY:
Exclusion
* Received any other therapy (i.e., surgery, radiation, hormone treatment, biologic therapy, and/or chemotherapy) for the treatment of breast cancer
* Concurrent use of anti-neoplastic or anti-tumor agents not part of the study therapy, including chemotherapy, radiation therapy, immunotherapy, and hormonal anticancer therapy
* Receiving any other investigational agents
18 Years
120 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Barbara Ann Karmanos Cancer Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Elaina Gartner
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Elaina M. Gartner, MD
Role: PRINCIPAL_INVESTIGATOR
Barbara Ann Karmanos Cancer Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Clinical trial summary from the National Cancer Institute's PDQ® database
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
WSU-2006-138
Identifier Type: -
Identifier Source: secondary_id
CDR0000554965
Identifier Type: -
Identifier Source: org_study_id
NCT01654757
Identifier Type: -
Identifier Source: nct_alias
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.